Adrenaline for the Treatment of No-Reflow in Normotensive Patients
Status:
Completed
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
No-reflow is defined as the lack of myocardial perfusion despite opening of the epicardial
coronary vessels in the setting of percutaneous coronary intervention (PCI). It has been
demonstrated that either impaired flow or the absence of flow is associated with an increased
rate of mortality. Among available treatment options, intracoronary adenosine is widely used
in clinical practice, moreover, adrenaline is a safe alternative for the cases where use of
adenosine is limited due to presence of hypotension or bradycardia. Nonetheless, evidence
from retrospective and observational studies suggest that intracoronary adrenaline is well
tolerated and may exert encouraging effects in prompt recovery of flow in these patients.
However, very limited data are available on efficacy of intracoronary (IC) adrenaline in
normotensive patients. Therefore, this study is planned to study the hypothesis that;
intracoronary adrenaline is safe and has significantly higher efficacy as compared to
adenosine for the treatment of no-reflow in normotensive patients with acute coronary
syndrome.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Cardiovascular Diseases, Karachi